---
title: 'Alnylam, Intellia, Third Harmonic, Galvanize'
type: 'episode'
url: 'https://doc.social/episodes/alnylam-intellia-third-harmonic-galvanize'
show: 'Life Science Today'
show_url: 'https://doc.social/podcasts/life-science-today'
published: '2022-09-20'
audio: 'unavailable — the host retired the file'
---

# Alnylam, Intellia, Third Harmonic, Galvanize

A $900 raise, gene therapy news, a quick IPO, and merge three for $100MFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesAlnylam, Link 2, Link 3Intellia TherapeuticsThird Harmonic BioGalvanize TherapeuticsAbout the ShowLife…

## Summary

A $900 raise, gene therapy news, a quick IPO, and merge three for $100M

**Find out more at
**[https://LifeScienceTodayPodcast.com
](https://lifesciencetodaypodcast.com/)
**Story References
**[Alnylam](https://investors.alnylam.com/press-release?id=26936), [Link 2](https://investors.alnylam.com/press-release?id=26896), [Link 3](https://investors.alnylam.com/press-release?id=26921)
[Intellia Therapeutics](https://www.biospace.com/article/intellia-presents-promising-crispr-data-in-attr-cm-and-hae/)
[Third Harmonic Bio
](https://www.biospace.com/article/releases/third-harmonic-bio-announces-pricing-of-upsized-initial-public-offering-september-14-2022/?keywords=harmonic)[Galvanize Therapeutics**
**](https://www.biospace.com/article/with-100m-galvanize-absorbs-two-biotechs-to-advance-electric-pulse-therapies/?keywords=galvanize)
**About the Show
**Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.